Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
LL-37 structure

LL-37

Immune
Phase 1 Research
35%
Low-Moderate Risk
2/5

Dosing Protocol

Typical Dose 100 mcg
Range 50 - 200 mcg
Maintenance 100 mcg daily

Pharmacokinetics

Half-Life 4.0 hrs
Onset 30 min
Peak 1.5 hrs
Duration 8.0 hrs
Bioavailability 85%
Primary Route Subcutaneous

Administration

Routes Subcutaneous
Injection Sites Abdomen, Thigh
Needle Gauge 29-31G
Syringe Type Insulin
Timing Morning

Reconstitution

Diluent Bacteriostatic Water
Volume 1 mL
Concentration 1000 mcg/mL
Stability 14 days refrigerated
Vial Sizes 1 mg

Special Instructions

Start with low dose (50mcg) as injection site reactions common at higher doses. Has broad antimicrobial and immunomodulatory effects.